Visceral Adiposity,Insulin Resistance,and Type 2 Diabetes

Abstract

The worldwide prevalence of obesity and obesity-related diseases continues to rise. Insulin resistance, the metabolic syndrome, and type 2 diabetes are all associated with obesity. Visceral fat is now recognized to have metabolic, endocrine, and immune functions; increased visceral adiposity enhances the risk of metabolic and cardiovascular disorders. Potential mechanisms of this increased risk may include increased free fatty acid release and alterations in adipokines. Lifestyle interventions resulting in weight loss and loss of visceral fat can have a significant impact on cardiometabolic risk. Bariatric surgery has also been shown to improve insulin resistance, type 2 diabetes, and other comorbidities of obesity. Several medical therapies for type 2 diabetes or obesity also show promise for an impact on visceral adiposity-related comorbidities.

Keywords

visceral fat insulin resistance metabolic syndrome obesity type 2 diabetes

References

Procopiou M. , Phillipe J. The metabolic syndrome and type 2 diabetes: epidemiological figures and country specificities. Cerebrovasc Dis. 2005;20(suppl 1):2-8.

Klein S. , Allison DB , Heymsfield SB , et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health; Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30:1647-1652.

Balkau B. , Deanfield JE , Després JP , et al. International day for the evaluation of abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation . 2007;116:1942-1951.

Ford ES Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care . 2005;28:2745-2749.

Ogden CL , Yanovski SZ , Carroll MD , Flegal KM The epidemiology of obesity. Gastroenterology. 2007;132:2087-2102.

Nguyen NT , Magno CP , Lane KT , Hinojosa MW , Lane JS Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008 ;207:928-934.

Yusuf S. , Hawken S. , Ounpuu S. , et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640-1649.

Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.

Preis SR , Hwang S. , Coady S. , et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119:1728-1735.

10.

Wild S. , Roglic G. , Green A. , Sicree R. , King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.

11.

Deckelbaum RJ , Williams CL Childhood obesity: the health issue . Obes Rev. 2001;9(suppl 4):2398-2438.

12.

Pinhas-Hamile O. , Dolan LM , Daniels SR , Standiford D. , Khoury PR , Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996;128:608-615.

13.

Sinaiko AR , Jacobs DR Jr , Steinberger J. , et al. Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors . J Pediatr. 2001;139:700-707.

14.

Sinha R. , Fisch G. , Teague B. , et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002; 346:802-810.

15.

Janssen I. , Katzmarzyk PT , Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79:379-384.

16.

Carey VJ , Walters EE , Colditz GA , et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses’ Health Study. Am J Epidemiol . 1997;145:614-619.

17.

Janssen I. , Katzmarzyk PT , Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med. 2002;162:2074-2079.

18.

Karter AJ , D’Agostino RB , Mayer-Davis EJ , et al. Abdominal obesity predicts declining insulin sensitivity in non-obese normoglycaemics: the Insulin Resistance Atherosclerosis Study (IRAS) . Diabetes Obes Metab. 2005;7:230-238.

19.

Després J. , Lemieux I. , Bergeron J. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28:1039-1049.

20.

Saltiel AR , Kahn CR Insulin signaling and the regulation of glucose and lipid metabolism . Nature. 2001;414:799-806.

21.

Semple RK , Sleigh A. , Murgatroyd PR , et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009 ;119:315-22.

22.

Roden M. , Price TB , Perseghin G. , et al. Mechanism of free fatty acid-induced insulin resistance in humans . J Clin Invest. 1996;97:2859-2865.

23.

Randle PJ , Garland PB , Newsholme EA , Hales CN The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus . Ann N Y Acad Sci. 1965;131:324-333.

24.

Kahn SE , Hull RL , Utzschneider KM Mechanisms linking obesity to insulin resistance and type 2 diabetes . Nature. 2006;444:840-846.

25.

Bergman RN , Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab. 2000;11:351-359.

26.

Saiki A. , Miyashita Y. , Wakabayasi K. , Kameda N. , Shirai K. Reduction of visceral adiposity after operation in a subject with insulinoma . J Atheroscler Thromb. 2004;11:209-214.

27.

Weyer C. , Bogardus C. , Mott DM , Pratley RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest . 1999;104:787-794.

28.

Muoio DM , Newgard CB Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:193-205.

29.

Butler AE , Janson J. , Bonner-Weir S. , Ritzel R. , Rizza RA , Butler PC Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.

30.

Lafontan M. , Girard J. Impact of visceral adipose tissue on liver metabolism part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab. 2008;34:317-327.

31.

Jennings CL , Lambert EV , Collins M. , Levitt NS , Goedecke JH The atypical presentation of the metabolic syndrome components in black African women: the relationship with insulin resistance and the influence of regional adipose tissue distribution. Metabolism. 2009 ;58:149-157.

32.

Karelis AD , St-Pierre DH , Conus F. , Rabasa-Lhoret R. , Poehlman ET

Metabolic and body composition factors in subgroups of obesity: what do we know?

J Clin Endocrinol Metab. 2004;89:2569-2575.

33.

Miyazaki Y. , Glass L. , Triplitt C. , Wajcberg E. , Mandarino LJ , DeFronzo RA Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;283:E1135-E1143.

34.

Seidell JC , Björntorp P. , Sjöström L. , Kvist H. , Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and c-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897-901.

35.

Pouliot MC , Després JP , Nadeau A. , et al. Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992;41:826-834.

36.

Barzilai N. , She L. , Liu BQ , et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes . 1999 ;48:94-98.

37.

Gabriely I. , Ma XH , Yang XM , et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process ? Diabetes. 2002;51:2951-2958.

38.

Carroll JF , Franks SF , Smith AB , Phelps DR Visceral adipose tissue loss and insulin resistance 6 months after laparoscopic gastric banding surgery: a preliminary study. Obes Surg. 2009;19:47-55.

39.

Thörne A. , Lönnqvist F. , Apelman J. , Hellers G. , Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord . 2002;26:193-199.

40.

Sims EAH. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50:1499-1504.

41.

Wu CH , Heshka S. , Wang J. , et al. Truncal fat in relation to total body fat: influences of age, sex, ethnicity and fatness. Int J Obes ( Lond). 2007;31:1384-1391.

42.

Lovejoy JC , Champagne CM , de Jonge L. , Xie H. , Smith SR Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond ). 2008;32:949-958.

43.

Toth MJ , Tchernof A. , Sites CK , Poehlman ET Menopause-related changes in body fat distribution. Ann N Y Acad Sci. 2000;904:502-506.

44.

Kanaley JA , Sames C. , Swisher L. , et al. Abdominal fat distribution in pre- and postmenopausal women: the impact of physical activity, age, and menopausal status. Metabolism. 2001;50:976-982.

45.

Kanaley JA , Giannopoulou I. , Tillapaugh-Fay G. , Nappi JS , Ploutz-Snyder LL Racial differences in subcutaneous and visceral fat distribution in postmenopausal black and white women. Metabolism. 2003;52:186-191.

46.

Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens. 2006;15:173-178.

47.

Smas CM , Sul HS Control of adipocyte differentiation. Biochem J. 1995;309:697-710.

48.

Drolet R. , Richard C. , Sniderman AD , et al. Hypertrophy and hyperplasia of abdominal adipose tissue in women . Int J Obes (Lond). 2008;32:283-291.

49.

Meek S. , Nair KS , Jensen MD Insulin regulation of regional free fatty acid metabolism. Diabetes. 1999;48:10-14.

50.

Mittelman SD , Van Citters GW , Kirkman EL , Bergman RN Extreme insulin resistance of the central adipose tissue in vivo. Diabetes . 2002;51:755-761.

51.

Jensen MD

Is visceral fat involved in the pathogenesis of the metabolic syndrome?

Human model. Obesity. 2006;14(suppl 1): 20S-24S.

52.

Gastaldelli A. , Cusi K. , Pettiti M. , et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects . Gastroenterology. 2007;133:496-506.

53.

Morino K. , Peterson KF , Schulman GI Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55(suppl 2):S9-S15.

54.

Samuel VT , Liu ZX , Qu XQ , et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345-32353.

55.

Schulman GI Cellular mechanisms of insulin resistance . J Clin Invest. 2000;106(2):171-176.

56.

Park E. , Wong V. , Guan X. , Oprescu AI , Giacca A. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J Endocrinol. 2007;195:323-331.

57.

Suganami T. , Tanimoto-Koyama K. , Nishida J. , et al. Role of the Toll-like receptor 4/NF-κB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages . Arterioscler Thromb Vasc Biol. 2007;27:84-91.

58.

Fain JN , Bahouth SW , Madan AK TNFα release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord. 2004;28:616-622.

59.

Cartier A. , Lemieux I. , Alméras N. , Tremblay A. , Bergeron J. , Després J-P. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-α in men. J Clin Endocrinol Metab. 2008;93:1931-1938.

60.

Hotamisligil GS , Shargill NS , Spiegelman BM Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance . Science . 1993;259:87-91.

61.

Ruan H. , Hacohen N. , Golub TR , Van Parijs L. , Lodish HF Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes. 2002;51:1319-1336.

62.

Gonzalez-Gay MA , DeMatias JM , Gonzalez-Juanatey C. , et al. Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83-86.

63.

Kiortsis DN , Mavridis AK , Vasakos S. , Nikas SN , Drosos AA Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis . Ann Rheum Dis. 2005 ;64:765-766.

64.

Dominguez H. , Storgaard H. , Rask-Madsen C. , et al. Metabolic and vascular effects of tumor necrosis factor-α blockade with enteracept in obese patients with type 2 diabetes. J Vasc Res. 2005;42:517-525.

65.

Bernstein LE , Berry J. , Kim S. , Canavan B. , Grinspoon SK Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166:902-908.

66.

Fain JN , Madan AK , Hiler ML , Cheema P. , Bahouth SW Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004 ;145:2273-2282.

67.

Lappas M. , Yee K. , Permezel M. , Rice GE Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-κB and IκB kinase pathway to regulate the release of pro-inflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology . 2005;146:1491-1497.

68.

Greenberg AS , Nordan RP , McIntosh J. , Calvo JC , Scow RO , Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 1992;52:4113-4116.

69.

Stouthard JML , Romijn JA , Van Der Poll T. , et al. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol Endocrinol Metab . 1995;268:E813-E819.

70.

Nonogaki K. , Fuller GM , Fuentes NL , et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats . Endocrinology. 1995;136:2143-2149.

71.

Steensberg A. , van Hall G. , Osada T. , Sacchetti M. , Saltin B. , Pedersen BK Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol . 2000;529:237-242.

72.

Febbraio MA , Pedersen BK Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev. 2005;33:114-119.

73.

Glund S. , Krook A. Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol (Oxf). 2008;192:37-48.

74.

Cota D. , Woods SC The role of the endocannabinoid system in the regulation of energy homeostasis . Curr Opin Endocrinol Diabetes Obes. 2005 ;12:338-351.

75.

Blüher M. , Engeli S. , Klöting N. , et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053-3060.

76.

Côté M. , Matias I. , Lemieux I. , et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men . Int J Obes (Lond ). 2007;31:692-699.

77.

Herling AW , Kilp S. , Juretschke H-P. , Neumann-Haefelin C. , Gerl M. , Kramer W. Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant. Int J Obes ( Lond). 2008;32:1363-1372.

78.

Herling AW , Kilp S. , Elvert R. , Haschke G. , Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats. Endocrinology. 2008;149:2557-2566.

79.

Jbilo O. , Ravinet-Trillou C. , Arnone M. , et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005;19:1567-1569.

80.

Seckl JR , Morton NM , Chapman KE , Walker BR Glucocorticoids and 11beta-hydroysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res. 2004;59:359-393.

81.

Bujalska IJ , Kumar S. , Hewison M. , Stewart PM Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology. 1999;140:3188-3196.

82.

Michailidou Z. , Jensen MD , Dumesic DA , et al. Omental 11β-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity. 2007;15:1155-1163.

83.

Purnell JQ , Kahn SE , Samuels MH , Brandon D. , Loriaux DL , Brunzell JD Enhanced cortisol production rates, free cortisol, and 11β-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab. 2009;296:E351-E357.

84.

Paulsen SK , Pedersen SB , Fisker S. , Richelsen B. 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity. 2007 ;15:1954-1960.

85.

Tomlinson JW , Sherlock M. , Hughes B. , et al. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab. 2007;92:857-864.

86.

Sandeep TC , Andrew R. , Homer NZ , Andrews RC , Smith K. , Walker BR Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone . Diabetes. 2005;54:872-879.

87.

Andrews RC , Rooyackers O. , Walker BR Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxelone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:285-291.

88.

Sobel BE Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation. 1999;99:2496-2498.

89.

Kohler HP , Grant PJ Plasminogen-activator inhibitor type 1 and coronary artery disease . N Engl J Med. 2000;342:1792-1801.

90.

Cigolini M. , Targher G. , Bergamo Andreis IA , Tonoli M. , Agostino G. , DeSandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men . Arterioscler Thromb Vasc Biol. 1996;16:368-374.

91.

Alessi M. - C. Juhan - Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences . Arterioscler Thromb Vasc Biol. 2006;26:2200-2207.

92.

Lindeman JHN , Pijl H. , Toet K. , et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes ( Lond). 2007;31:1671-1679.

93.

Brogren H. , Sihlbom C. , Wallmark K. , et al. Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin. Thromb Res. 2008;122:271-281.

94.

Nannipieri M. , Bonotti A. , Anselmino M. , et al. Pattern of expression of adiponectin receptors in human adipose tissue depots and its relation to the metabolic state. Int J Obes ( Lond). 2007;31:1843-1848.

95.

Hanley AJG , Bowden D. , Wagenknecht LE , et al. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans . J Clin Endocrinol Metab. 2007;92:2665-2671.

96.

Mather KJ , Funahashi T. , Matsuzawa Y. , et al; Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 2008;57:980-986.

97.

Koenig W. , Khuseyinova N. , Baumert J. , Meisinger C. , Löwel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369-1377.

98.

Broedl UC , Lebherz C. , Lehrke M. , et al. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS ONE . 2009;4:e4733.

99.

Fain JN , Buehrer B. , Tichansky DS , Madan AK Regulation of adiponectin release and demonstration of adiponectin mRNA as well as release by the non-fat cells of human omental adipose tissue . Int J Obes (Lond). 2008;32:429-435.

100.

US Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med. 2003;139:930-932.

101.

World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. Geneva, Switzerland: World Health Organization; 1998.

102.

NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Heart, Lung, and Blood Institute ; 1998. NIH publication 98-4083.

103.

Lau DCW , Douketis JD , Morrison KM , Hramiak IM , Sharma AM , Ur E. ; Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007 ;176(suppl 8):S1-S13.

104.

National Collaborating Centre for Primary Care. Obesity: Guidance on the Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. London : National Institute of Health and Clinical Excellence ; 2006.

105.

Grundy SM , Cleeman JI , Daniels SR , et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement . Circulation. 2005;112:2735-2752.

106.

International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/MetS_def_update2006.pdf. Accessed May 27, 2009.

107.

Razak F. , Anand SS , Shannon H. , et al; SHARE Investigators. Defining obesity cut points in a multiethnic population. Circulation . 2007;115:2111-2118.

108.

Scott AL , Mustafa T. , Birmingham CL , Jiri JF Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism. 2003;52:1295-1301.

109.

Galuska DA , Will JC , Serdula MK , Ford ES Are health care professionals advising obese patients to lose weight? JAMA . 1999;282:1576-1578.

110.

Levy BT , Williamson PS Patient perceptions and weight loss of obese adults. J Fam Pract. 1998;27:285-329.

111.

Rana JS , Li TY , Manson JE , Hu FB Adiposity compared with physical inactivity and risk of type 2 diabetes in women. Diabetes Care. 2007;30:53-58.

112.

Zhang C. , Rexrode KM , van Dam RM , Li TY , Hu FB Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation . 2008;117:1658-1667.

113.

Chaston TB , Dixon JB Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes ( Lond ). 2008;32:619-628.

114.

Ohkawara K. , Tanaka S. , Miyachi M. , Ishikawa-Takata K. , Tabata I. A dose-response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials. Int J Obes ( Lond). 2007;31:1786-1797.

115.

Kay SJ , Fiatarone Singh MA The influence of physical activity on abdominal fat: a

116.

systematic review of the literature. Obes Rev. 2006;7:183-200.

117.

Jakicic JM , Clark K. , Coleman E. , et al. American College of Sports Medicine position stand: appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2001;33:2145-2156.

118.

Ross R. , Dagnone D. , Jones PJH , et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. Ann Intern Med. 2000;133:92-103.

119.

Lee S. , Kuk JL , Davidson LE , et al. Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without type 2 diabetes. J Appl Physiol. 2005;99:1220-1225.

120.

Curioni CC , Lourenço PM Long-term weight loss after diet and exercise: a systematic review. Int J Obes ( Lond ). 2005;29:1168-1174.

121.

Nicklas BJ , Wang X. , You T. , et al. Effect of exercise intensity on abdominal fat loss during calorie restriction in overweight and obese postmenopausal women: a randomized, controlled trial. Am J Clin Nutr. 2009;89:1043-1052.

122.

O’Leary V. , Marchetti CM , Krishnan RK , Stetzer BP , Gonzalez F. , Kirwan JP Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol. 2006;100:1584-1589.

123.

Riches FM , Watts GF , Hua J. , et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab. 1999;84:2854-2861.

124.

Viljanen APM , Iozzo P. , Borra R. , et al. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab. 2009;94:50-55.

125.

Mazzail G. , Di Francesco V. , Zoico E. , et al. Interrelations between fat distribution, muscle lipid content, adipocytokines, and insulin resistance: effect of moderate weight loss in older women. Am J Clin Nutr. 2006;84:1193-1199.

126.

Belza A. , Toubro S. , Stender S. , Astrup A. Effect of diet-induced energy deficit and body fat reduction on high-sensitive CRP and other inflammatory markers in obese subjects. Int J Obes (Lond). 2009;33:456-464.

127.

Herder C. , Peltonen M. , Koenig W. , Sütfels, et al; Finnish Diabetes Prevention Study Group. Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia. 2009;52:433-442.

128.

Douketis JD , Macie C. , Thabane L. , Williamson DF Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes ( Lond). 2005;29:1153-1167.

129.

Tuomilehto J. , Lindström J. , Eriksson JG , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.

130.

Laaksonen DE , Lindström J. , Lakka TA , et al; Finnish Diabetes Prevention Study Group. Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study . Diabetes. 2005;54:158-165.

131.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med. 2002;346:393-403.

132.

Ackermann RT , Finch EA , Brizendine E. , Zhou H. , Marrero DG Translating the Diabetes Prevention Program into the community: the DEPLOY Pilot Study . Am J Prev Med . 2008;35:357-363.

133.

Whittemore R. , Melkus G. , Wagner J. , Dziura J. , Northrup V. , Grey M. Translating the Diabetes Prevention Program to primary care: a pilot study. Nurs Res. 2009;58:2-12.

134.

Seufert J. , Lubben G. , Dietrick K. , Bates PC A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus . Clin Ther. 2004;26:805-818.

135.

Golay A. Metformin and body weight. Int J Obes ( Lond). 2008;32:61-72.

136.

Lord J. , Thomas R. , Fox B. , Acharya U. , Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. BJOG. 2006;113:817-824.

137.

Shadid S. , Jensen MD Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care . 2003;26:3148-3152.

138.

Miyazaki Y. , Mahankali A. , Matsudo M. , et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients . J Clin Endocrinol Metab. 2002;87:2784-2791.

139.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-854.

140.

Davies M. , Khunti K. Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine. Diabetes Obes Metab. 2008;10(suppl 2): 42-49.

141.

Hollander P. , Cooper J. , Bregnhoj J. , Pedersen CB A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976-1987.

142.

Monami M. , Marchionni N. , Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes: a meta-analysis. Diabetes Obes Metab. 2009 ;11:372-378.

143.

Florentin M. , Liberopoulous EN , Mikhailidis DP , Elisaf MS Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2008 ;9:1705-1720.

144.

Buse JB , Klonoff DC , Nielsen LL , et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007 ;29:139-153.

145.

Bhushan R. , Elkind-Hirsch KE , Bhushan M. , Bulter WJ , Duncan K. , Marrioneaux O. Exenatide use in the management of metabolic syndrome: a retrospective database study . Endocr Pract. 2008;14:993-999.

146.

Aronne L. , Fujioka K. , Aroda V. , et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977-2883.

147.

Smith SR , Blundell JE , Burns C. , et al. Pramlintide treatment reduces 24-hr caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007;293:E620-E627.

148.

Wysham C. , Lush C. , Zhang B. , Maier H. , Wilhelm K. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin. 2008;24:79-85.

149.

Kelley DE , Kuller LH , McKolanis TM , Harper P. , Mancino J. , Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care . 2004;27:33-40.

150.

Rubio M. , Gargallo M. , Millan AI , Moreno B. Drugs in the treatment of obesity: sibutramine, orlistat, and rimonabant . Public Health Nutr. 2007;10:1200-1205.

151.

Van Gaal LF , Wauters MA , Peiffer FW , De Leeuw IH Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obes Relat Metab Disord. 1998;22(suppl 1): S38-S40.

152.

Perkins JM , Davis SN Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep. 2008;8:12-19.

153.

Després JP , Golay A. , Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134.

154.

Scheen AJ , Finer N. , Hollander P. , et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet. 2006;368:1660-1672.

155.

Pories WJ , MacDonald KG Jr , Flickinger EG , et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg. 1992;215:633-642.

156.

Ybarra J. , Biano-Vaca F. , Fernandez S. , et al. The effects of liposuction removal of subcutaneous abdominal fat on lipid metabolism are independent of insulin sensitivity in normal-overweight individuals. Obes Surg. 2008;18:408-414.

157.

Klein S. , Fontana L. , Young VL , et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549-2457.

158.

Mohammed BS , Cohen S. , Reeds D. , Young VL , Klein S. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease . Obesity . 2008;16:2645-2651.

159.

D’Andrea F. , Grella R. , Rizzo MR , et al. Changing the metabolic profile by large-volume liposuction: a clinical study conducted with 123 obese women . Aesthetic Plast Surg. 2005;29:472-478.

160.

Buchwald H. , Avidor Y. , Braunwald E. , et al. Bariatric surgery: a systemic review and meta-analysis. JAMA. 2004;292:1724-1737.

161.

Wickremesekera K. , Miller G. , Naotunne TD , Knowles G. , Stubbs RS Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15:474-481.

162.

Rubino F. , Gagner M. , Gentileschi P. , et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-242.

163.

Dixon JB Obesity and diabetes: the impact of bariatric surgery on type 2 diabetes . World J Surg. 2009;33:2014-2021.

164.

Busetto L. , Tregnaghi A. , Bussolotto M. , et al. Visceral fat loss evaluated by total body magnetic resonance imaging in obese women operated with laparoscopic adjustable silicone gastric banding. Int J Obes Relat Metab Disord. 2000;24:60-69.

165.

Dixon JB , O’Brien PE , Playfair J. , et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.

166.

Sjostrom L. , Lindroos A-K. , Peltonen M. , et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery . N Engl J Med . 2004;351:2683-2693.

167.

DeMaria EJ Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176-2183.

168.

Nestler JE Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med. 2008;358:47-54.

169.

Kim CH , Younossi ZM Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med . 2008;75:721-728.

170.

Petta S. , Muratore C. , Craxi A. Nonalcoholic fatty liver disease pathogenesis: the present and the future . Dig Liver Dis. 2009;41:615-625.

171.

Gary-Bobo M. , Elachouri G. , Gallas JF , et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007 ;46:122-129.

172.

Umpierrez GE , Smiley D. , Robalino G. , et al. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:609-614.

173.

Saad MF , Rewers M. , Selby J. , et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis Study. Hypertension. 2004;43:1324-1331.

174.

Muniyappa R. , Montagnan M. , Koh KK , Quon MJ Cardiovascular actions of insulin. Endocr Rev. 2007;28:463-491.

175.

Punjabi NM , Sorkin JD , Katzel LI , et al. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med. 2002;165:677-682.